Assessment of the mental status of patients with rosacea

Rosacea is a common chronic skin disease that significantly impairs patients’ quality of life. Various phenotypic characteristics and the localization on the face can have a negative impact on mental health and socialization, causing anxiety and depression in patients with rosacea. The aim of the study was to determine baseline levels of anxiety and depression in patients with erythematotelangiectatic telangiectatic and papulopustular rosacea and their combination and to compare the effect of combination therapy on patients’ psychoemotional state. We observed 45 patients with a diagnosis of erythematous telangiectatic rosacea and papulo-pustular subtypes of mild and moderate severity and their combination. Patients were divided into three groups according to the choice of combination of treatment methods. In group No. 1: 15 patients received botulinum toxin therapy with topical azelaic acid plus ivermectin. In group No. 2: 15 patients received PDL 595 nm procedure in combination with the topical therapy azelaic acid plus ivermectin. In group No. 3: 15 patients received botulinum toxin therapy with incobotulotoxin in combination with ILC 595 nm and topical azelaic acid therapy in combination with ivermectin. 26.7 % of the patients included in the study showed a deterioration in skin appearance due to emotional strain and stress. All patients showed subclinical manifestations of anxiety and depression according to the Hospital anxiety and depression scale (HADS). In addition, the mental state and anxiety of patients with rosacea can be significantly improved after treatment. Combination therapy with ivermectin, azelaic acid, LC 595 nm and botulinum therapy brings maximum results in normalizing the psychoemotional state. Alleviating the clinical manifestations of rosacea helps to reduce the level of anxiety and depression in patients with rosacea.

1. Kruglova L. S., Matushevskaya Yu. I. Current issues in the treatment of patients with a combination of subtypes of rosacea. Medical alphabet. Dermatology. 2021. No. 27. pp. 42–47. (In Russ.). DOI: 10.33667/2078–5631–2021–27–42–46

2. Ahn C. S., Huang W. W. Rosacea pathogenesis. Dermatol Clin. 2018. Vol. 36. № 2. P. 81-86.

3. Two A. M., Wu W., Gallo R. L., Hata T. R. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015. Vol. 72. № 5. P. 749−758.

4. Chang J., Wang Y., Sun D., et al. Characterization of rosacea in Chinese: an analysis of 254 cases. J Cosmet Dermatol. 2021. Vol. 20. № 11. P. 3666–3671.

5. Dirschka T., Micali G., Papadopoulos L., Tan J., Layton A., Moore S. Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey. Dermatol Ther (Heidelb). 2015. Vol. 5. № 2. P. 117–127.

6. Hung C. T., Chiang C. P., Chung C. H., et al. Risk of psychiatric disorders in rosacea: a nationwide, population-based, cohort study in Taiwan. J Dermatol. 2019. Vol. 46. № 2. P. 110–116.

7. Singam V., Rastogi S., Patel K. R., Lee H. H., Silverberg J. I. The mental health burden in acne vulgaris and rosacea: an analysis of the US National Inpatient Sample. Clin Exp Dermatol. 2019. Vol. 44. № 7. P. 766−772.

8. Wang B., Huang Y., Tang Y., et al. Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the prospective rosacea refractory erythema randomized clinical trial. J Am Acad Dermatol. 2023. Vol. 88. № 6. P. 1300–1307.

9. Акне и розацеа / Под редакцией Кругловой Л. С. ГЭО- ТАР-Медиа. 2021. 207 с. Acne and rosacea / Edited by Kruglova L. S. GEOTAR-Media. 2021. 207 p. (In Russ.).

10. Ginsburg I. H, Link B. G. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989. Vol. 20. № 1. P. 53–63.

11. Hrehorow E., Salomon J., Matusiak L., Reich A., Szepietowski J. C. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012. Vol. 92. № 1. P. 67–72.

12. Schmid-Ott G., Kuensebeck H. W., Jaeger B., et al. Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Derm Venereol. 1999. Vol. 79. № 6. P. 443–447.

13. Fried R. G. Acne vulgaris: the psychosocial and psychological burden of illness. Dermatologist. 2013. Vol. 21. P. 2773.

14. Ongenae K., Dierckxsens L., Brochez L., van Geel N., Naeyaert J. M. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology. 2005. Vol. 210. № 4. P. 279–285.

15. Schmid-Ott G., Kunsebeck H. W., Jecht E., et al. Stigmatization experience, coping and sense of coherence in vitiligo patients. J Eur Acad Dermatol Venereol. 2007. Vol. 21. № 4. P. 456–461.

16. Cardwell L., Farhangian M., Alinia H., Kuo S., Feldman S. Psychological disorders associated with rosacea: analysis of unscripted comments. J Dermatol Derm Surg. 2015. Vol. 19. P. 99–103.

17. Dirschka T., Micali G., Papadopoulos L., Tan J., Layton A., Moore S. Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey. Dermatol Ther (Heidelb). 2015. Vol. 5. № 2. P. 117–127.

18. Moustafa F., Lewallen R. S., Feldman S. R. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014. Vol. 71. № 5. P. 973–980.

19. Park K., Hyun M., Jeong S., et al. Botulinum toxin for the treatment of refractory erythema and flushing rosacea. Dermatology. 2015. Vol. 230. № 4. P. 299–301.

20. Heisig M., Reich A. Psychosocial aspects of rosacea with a focus on anxiety and depression. Clin Cosmet Investig Dermatol. 2018.Vol. 11. P. 103–107. DOI: 10.2147/CCID.S 126850.

21. The jamovi project. Выпуск 2.3: программа. 2022. URL: https://www.jamovi.org (дата обращения: 21.04.2023). Режим доступа: для зарегистрир. пользователей.

22. A Language and environment for statistical computing. Выпуск 4.1: программа. R Core Team. 2021. URL: https://cran.r-project.org (дата обращения: 21.04.2023). Режим доступа: для зарегистрир. пользователей.